Publications

Mihaila I, Hartley SL, Handen BL, Bulova PD, Tumuluru RV, Devenny DA, Johnson SC, Lao PJ, Christian BT. (2017). Leisure Activity in Middle-Aged and Older Adults with Down Syndrome. Intellectual and Developmental Disabilities, 55(2), 97-109. doi:10.1352/1934-9556-55.2.97

Lao PJ, Betthauser TJ, Hillmer AT, Price JC, Klunk WE, Mihaila I, Higgins AT, Bulova PD, Hartley SL, Hardison R, Tumuluru RV, Murali D, Mathis CA, Cohen AD, Barnhart TE, Devenny DA, Mailick MR, Johnson SC, Handen BL, Christian BT. (2016) The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimer's & Dementia. 12(4):380-90. doi: 10.1016/j.jalz.2015.05.013.

Annus T; Wilson LR, Hong YT; Acosta-Cabronero J; Fryer TD; Cardenas-Blanco A; Smith R; Boros I; Coles JP; Aigbirhio FI; Menon DK; Zaman SH; Nestor PJ; & Holland AJ. (2016). The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimer’s & Dementia, 12(5); 538-545. DOI: http://dx.doi.org/10.1016/j.jalz.2015.07.490.

Mihaila J, Handen SL, Price JC, Bulova PD, Tumuluru RV, Devenny DA, Mailick MR, Johnson SC Lao PJ, Christian BT, Hartley SL. (2016). Leisure Activity in Middle-Aged and Older Adults with Down Syndrome. Intellectual and Developmental Disabilities. In Press.

Raha AA, Henderson JW, Stott SR, Vuono R, Foscarin S, Friedland RP, Zaman SH, Raha-Chowdhury R. (2016). Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model. The Journal of Alzheimer's Disease, In press.

Sabbagh M, Edgin J. (2016). Clinical Assessment of Cognitive Decline in Adults with Down Syndrome. Current Alzheimer Research, 13(1):30-4.

Clark LR, Racine AM, Koscik RL, Okonkwo OC, Nicholas CR, Oh JM, Engleman CD, Hermann B, Carlsson CM, Asthana S, Rowley HA, Sager MA, Christian BT, Johnson SC. (2016). Amyloid burden predicts decline in memory function in middle-aged at-risk cohort: Findings from the WRAP study. Alzheimer's & Dementia, In Press.

SH Zaman & N Bouras. (2016). Managing mental health problems in people with intellectual disabilities. In Carr, A., Linehan, C., O'Reilly, G., Walsh, P. N., & McEvoy, J. (Eds.), The Handbook of Intellectual Disability and Clinical Psychology Practice, 2nd Edition, London, Routledge.

Willette AA, Bendlin BB, Starks E, Birdsill A, Johnson SC, Christian BT, Okonkwo OC, LaRue A, Hermann BP, Koscik RL, Jonaitis EM, Sager MA, Asthana S. (2015). Association of insulin resistance with cerebral glucose utilization in late middle-aged adults at risk for Alzheimer Disease. JAMA Neurology, 72(9):1013-1020. PMCID: PMC4570876.

Sabbagh MN, Chen K, Rogers J, Fleisher AS, Liebsack C, Bandy D, Belden C, Protas H, Thiyyagura P, Liu X, Roontiva A, Luo J, Jacobson S, Malek-Ahmadi M, Powell J, Reiman EM. (2015). Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer’s Dementia. Alzheimer's & Dementia, 11(8): 994-1004.

Hartley D; Blumenthal T; Carrillo M; DiPaolo G; Esralew L; Gardiner K; Granholm AC; Iqbal K; Krams M; Lemere C; Lott I; Mobley W; Ness S; Nixon R; Potter H; Reeves R; Sabbagh M; Silverman W; Tycko B; Whitten M; Wisniewski T. (2015). Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimer's & Dementia, 11(6):700-9. doi: 10.1016/j.jalz.2014.10.007.

Anand K, Sabbagh M. (2016). Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease. Expert Opinion on Investigational Drugs, 24(10):1355-60. doi:10.1517/13543784.2015.1075002.

Jennings D; Seibyl J; Sabbagh M; Lai F; Hopkins W; Bullich S; Gimenez M; Reininger C; Putz B; Stephens A; Catafau AM; Marek K. (2015). Age dependence of brain beta-amyloid deposition in Down syndrome: An [18F]florbetaben PET study. Neurology 3;84(5):500-7. doi: 10.1212/WNL.0000000000001212.

Hartley SL, Handen BL, Devenny DA, Hardison R, Mihaila I, Price JC, et al. (2014). Cognitive functioning in relation to brain amyloid-beta in healthy adults with Down syndrome. Brain, 137, 2556-63. doi:10.1093/brain/awu173.

Johnson SC, Christian BT, Okonkwo O, Oh J, Harding S, Xu G, Hillmer AT, Wooten DW, Murali D, Barnhart T, Hall L, Klunk W, Mathis C, Bendlin BB, Gallagher CL, Carlsson CM, Rowley H, Hermann BP, Dowling NM, Asthana S, Sager MA. (2014). Amyloid burden and neural function in people at risk for AD. Neurobiology of Aging, 35(3):576-584.PMCID: PMC4018215.

LR Wilson, T Anuus, SH Zaman & AJ Holland. (2014). Understanding the process, links between Down syndrome and dementia. In K. Watchman (Ed.), Intellectual Disability and Dementia Research into Practice. (pp. 34-52). Jessica Kingsley Publishers, London UK & Philadelphia, PA.

Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, et al. (2012). Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimer's & Dementia, 8, 496-501. doi:10.1016/j.jalz.2011.09.229.

d’Abrera JC; Holland AJ; Landt J; Stocks-Gee G; & Zaman SH. (2011). A neuroimaging proof of principle study of Down’s syndrome and dementia: ethical and methodological challenges in intrusive research. Journal of Intellectual Disability Research, 57(2); 105-118.

Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, Pontecorvo M, Mintun M, Skovronsky D, Jacobson SA, Sue LI, Liebsack C, Charney AS, Cole L, Belden C, Beach TG. (2011). Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. Archives of Neurology, 68:1461-1466. (PMC-3346179).

Landt J, D'Abrera JC, Holland AJ, Aigbirhio FI, Fryer TD, Canales R, Hong YT, Menon DK, Baron J, Zaman SH. (2011). Using Positron Emission Tomography and Carbon 11–Labeled Pittsburgh Compound B to Image Brain Fibrillar β-Amyloid in Adults With Down Syndrome Safety, Acceptability, and Feasibility. Archives of Neurology, 68(7):890-896. doi:10.1001/archneurol.2011.36

Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. (2007). Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. Journal of Neuroscience, 6;27(23):6174-84.

Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. (2005). Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow & Metabolism, 25(11):1528-47.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 55(3):306-19.